Sequoia Financial Advisors LLC grew its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,898 shares of the medical research company's stock after acquiring an additional 2,664 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Agilent Technologies were worth $4,554,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA boosted its holdings in shares of Agilent Technologies by 3.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company's stock valued at $2,314,784,000 after acquiring an additional 525,214 shares during the last quarter. State Street Corp lifted its stake in shares of Agilent Technologies by 1.2% in the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company's stock worth $1,903,498,000 after purchasing an additional 158,175 shares during the period. Geode Capital Management LLC lifted its stake in shares of Agilent Technologies by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 6,948,679 shares of the medical research company's stock worth $1,028,241,000 after purchasing an additional 30,610 shares during the period. Cantillon Capital Management LLC lifted its stake in shares of Agilent Technologies by 0.5% in the 4th quarter. Cantillon Capital Management LLC now owns 3,316,557 shares of the medical research company's stock worth $445,546,000 after purchasing an additional 17,627 shares during the period. Finally, Van ECK Associates Corp lifted its stake in shares of Agilent Technologies by 8.7% in the 4th quarter. Van ECK Associates Corp now owns 3,235,263 shares of the medical research company's stock worth $434,625,000 after purchasing an additional 258,358 shares during the period.
Insider Activity at Agilent Technologies
In related news, CEO Padraig Mcdonnell sold 1,911 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Agilent Technologies Price Performance
NYSE A opened at $117.21 on Friday. The stock has a market cap of $33.42 billion, a price-to-earnings ratio of 26.94, a PEG ratio of 3.40 and a beta of 1.11. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. Agilent Technologies, Inc. has a 12 month low of $117.17 and a 12 month high of $155.35. The company's 50 day moving average is $138.54 and its two-hundred day moving average is $138.13.
Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. As a group, research analysts anticipate that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.
Agilent Technologies Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.85%. Agilent Technologies's dividend payout ratio is currently 22.76%.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price objective on shares of Agilent Technologies from $157.00 to $155.00 and set an "overweight" rating on the stock in a research note on Monday, December 9th. JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 26th. StockNews.com upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Citigroup increased their price objective on shares of Agilent Technologies to $165.00 and gave the stock a "buy" rating in a research note on Thursday, December 19th. Finally, Sanford C. Bernstein lowered their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating on the stock in a research note on Tuesday, November 26th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $146.15.
View Our Latest Report on Agilent Technologies
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Featured Stories
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
